Gentler chemo tested for elderly cancer patients

NCT ID NCT07125183

Recruiting now Disease control Sponsor: University of Colorado, Denver Source: ClinicalTrials.gov ↗

First seen Oct 31, 2025 · Last updated May 15, 2026 · Updated 25 times

Summary

This study is testing whether giving a lower dose of the chemotherapy drug doxorubicin weekly, instead of the standard higher dose every three weeks, is effective and easier to tolerate for older patients (ages 65-100) with advanced soft tissue sarcoma. The main goal is to see if this schedule can control cancer growth for at least 12 weeks while causing fewer side effects. Researchers will also closely monitor patients' quality of life and collect blood and tumor samples to understand how the treatment affects the immune system.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

University Of Colorado Hospital
RECRUITING

Aurora, Colorado, 80045, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

SARCOMA